A Phase III, Open-Label, Randomised Study of Osimertinib with or without Datopotamab Deruxtecan (Dato-DXd), as First-Line Treatment in Participants with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer